UNLABELLED Cognitive impairment is a symptom of multiple sclerosis (MS). Different clinical forms of multiple sclerosis have different cognitive profiles, according to findings of previous studies which used extensive batteries of neuropsychological tests. OBJECTIVE To investigate cognitive profiles of Brazilian patients with relapsing-remitting multiple sclerosis (RRMS) and primary progressi...

#### Notable in Neurology This Week This issue features an article that investigates the safety of ocrelizumab people with relapsing and primary progressive multiple sclerosis; another examines whether a computer deep learning algorithm can detect MRI-negative focal cortical dysplasia. A featured Review neurologic conditions seen vaccines, including mRNA adenovirus vector coronavirus disease 2...

Multiple sclerosis (MS) is a chronic autoimmune disorder of central nervous system. This demyelinating disease affects more than 2.3 million people world wild. Most of patients are young adult. The most common type of MS is relapsing remitting multiple sclerosis (RRMS). However there is no cure, available modifying therapies has revolutionized the care of patients with RRMS. Interferon (IFN) be...

background: it has been reported that liver function alterations occur in 8–38% of patients with relapsing-remitting multiple sclerosis (rrms) treated with interferon-beta in controlled clinical trials or in prospective but non-controlled studies. we report herein a case of symptomatic liver dysfunction associated with two-year-period of regular interferon-beta-1a (avonex®) intramuscular inject...

results when the two ms groups were compared together, we found that cr was significantly increased (p value=0.008) and naa/cr was significantly decreased (p value=0.03) in non-enhancing lesions in ppms compared with rrms. there was no significant difference in naa, cho or naa/cho between the two ms subtypes. conclusion mrs is a potential way to differentiate ppms and rrms. objectives we compar...

The main aim of the study is to evaluate efficacy and safety profile Ocrelizumab (OCR), Rituximab (RTX), Cladribine (CLA), employed as Natalizumab (NTZ) exit-strategies in Relapsing-Remitting Multiple Sclerosis (RRMS) patients at high-risk for progressive multifocal leukoencephalopathy (PML).

Fast track appraisal (FTA) was adopted by NICE in 2017. This faster and more simplified process is mainly used for novel pharmaceutical agents that are considered bioequivalent to an already recommended drug with added advantages or reduced costs. In June 2022 FTA recommend diroximel fumarate (Vumerity) the management of relapsing remitting multiple sclerosis (RRMS). short article explores pote...

Abstract Background Cognitive dysfunction is common among patients with multiple sclerosis (MS); however, the determinants of cognitive are still unknown. This study aimed to investigate in a relatively large sample MS for rapid screening. Results Fifty-three (33.6%) had dysfunction. According Wechsler Memory Scale, relapsing-remitting (RRMS) and progressive (PMS) significantly lower scores tha...

background: intravenous immunoglobulin (ivig) is an established treatment of immune mediated demyelinating neuropathy including guillain-barré syndrome and chronic inflammatory demyelinating polyneuropathy. recent trials suggest its efficacy in treating relapsing- remitting multiple sclerosis. ivig exerts a number of effects, which may be beneficial in treating multiple sclerosis (ms): reductio...